A Survivorship Care Plan and Embedded Navigation Tool
NCT03424837 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 77
Last updated 2021-07-29
Summary
This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.
Conditions
Interventions
- BEHAVIORAL
-
ASCENT
ASCENT includes the following components: * Survivorship care plan created through the ASCENT tool * Online tool which assesses health care needs and facilitates receipt of care * A national-level navigator who helps the participant to access support services * Periodic reminders for the participant to pursue recommended survivorship care
Sponsors & Collaborators
- collaborator OTHER
-
Emory Healthcare
collaborator OTHER - collaborator OTHER
-
Memorial Sloan Kettering Cancer Center
collaborator OTHER -
H. Lee Moffitt Cancer Center and Research Institute
collaborator OTHER -
UNC Lineberger Comprehensive Cancer Center
collaborator OTHER -
Morehouse School of Medicine
collaborator OTHER - lead OTHER
Principal Investigators
-
Michael Harrison, M.D. · Duke University
-
Andrew Peterson, M.D. · Duke University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-11
- Primary Completion
- 2020-11-24
- Completion
- 2020-11-24
Countries
- United States
Study Locations
More Related Trials
-
Addressing Health Literacy With a Tailored Survivorship Care Plan
NCT06674863 ·Status: RECRUITING ·Phase: NA
-
Non-Interventional Study PREVENT
NCT02155998 ·Status: COMPLETED
-
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
NCT00161252 ·Status: WITHDRAWN
-
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
NCT03246347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924 ·Status: RECRUITING ·Phase: PHASE3
-
Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners
NCT04189770 ·Status: ACTIVE_NOT_RECRUITING
-
Active Surveillance in Prostate Cancer
NCT00490763 ·Status: COMPLETED
-
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
NCT03899077 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT05169970 ·Status: RECRUITING ·Phase: PHASE2
-
Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)
NCT03129854 ·Status: RECRUITING ·Phase: NA
-
Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy
NCT03070145 ·Status: COMPLETED ·Phase: NA
-
Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate
NCT01255891 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
NCT00242567 ·Status: COMPLETED ·Phase: PHASE3
-
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06305832 ·Status: RECRUITING ·Phase: PHASE2
-
Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
NCT06238596 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer
NCT06029036 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
NCT06575257 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
NCT07027124 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer
NCT03458247 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
NCT00148772 ·Status: COMPLETED ·Phase: PHASE2
-
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
NCT02278185 ·Status: COMPLETED ·Phase: PHASE2
-
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178 ·Status: RECRUITING ·Phase: PHASE3
-
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
NCT05781217 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
NCT05100472 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer
NCT03088124 ·Status: COMPLETED ·Phase: PHASE2